Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study
| Autor: | Galen L. Wampler, J. D. Ahlgren, John G. Fryer, M. Auerbach, Jacob J. Lokich, D. Fryer |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Nausea medicine.medical_treatment Gastroenterology Carboplatin chemistry.chemical_compound Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Mucositis Humans Aged Aged 80 and over Chemotherapy Leukopenia business.industry Hematology Middle Aged medicine.disease Surgery Pancreatic Neoplasms Regimen Oncology chemistry Fluorouracil Vomiting Female medicine.symptom business medicine.drug |
| Zdroj: | Annals of oncology : official journal of the European Society for Medical Oncology. 8(5) |
| ISSN: | 0923-7534 |
| Popis: | Summary Background Advanced pancreatic cancer is a rapidly fatal disease whose course has been little influenced by chemotherapy. Earlier studies have shown some modest promise for the combination of protracted infusional 5-fluorouracil (PIF) and cisplatin. We sought to evaluate a regimen of possibly lesser toxicity, PIF plus weekly carboplatin. Patients and Methods Fifty-four patients with advanced adenocarcinoma of the pancreas were treated with a regimen of protracted infusional fluorouracil 300 mg/m2/day for 70 days and carboplatin 100 mg/m2/weekly on weeks 1 through 10 of a 12-week cycle. After a two-week rest, cycles were repeated until progression. Results Median duration on treatment was 82 days (range 4–490 days). Toxicity was mild. Grade 3–4 toxicities were anemia 11%, leukopenia 6%, thrombocytopenia 2%, nausea/vomiting 7%, diarrhea 9%, mucositis 9%, and renal 2%. Response was evaluable in 47 patients. There were two complete and seven partial responses (17% overall objective response rate among all patients). Stable disease for greater than 12 weeks was seen in 19 patients (40%) and progression in 19 (40%). The median overall survival was 22 weeks (1–99), with 61 weeks median survival in responders (22–99). One-year survival was 13%. Conclusions Response and survival results with this regimen are at least equal to the best combination regimens reported, and were obtained with a low overall rate of serious toxicity. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|